Cellworks Group, Inc. is a leader in precision drug development and personalized therapy biosimulation. The Cellworks platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology. Backed by Artiman Ventures, Bering Capital, Sequoia Capital, UnitedHealth Group, and Agilent Ventures, Cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers, and software technologists working toward a common goal – attacking serious diseases to improve the lives of patients.